Dhruvitkumar Sutaria

11PUBLICATIONS
38CO-AUTHORS
Predictive and prognostic markersPharmaceutical delivery technologiesCancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 17, 2025
Quantifying Risk of Delayed QT Prolongation of Ipatasertib in Preclinical and Clinical Studies in Cancer Patients.

Victor Poon, Dhruvitkumar Sutaria, Rodney Prell

|Apr 27, 2024
Evaluation of Patient-Centric Sample Collection Technologies for Pharmacokinetic Assessment of Large and Small Molecules.

Sandhya Mandlekar, Dhruvitkumar S Sutaria, Xiaoyun Yang

|Mar 19, 2024
Clinical Pharmacology Considerations for the "Off-the-Shelf" Allogeneic Cell Therapies.

Hardik Mody, Dhruvitkumar S Sutaria, Dale Miles

|Jun 20, 2023
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer.

David Pook, Daniel M Geynisman, Joan Carles

|Apr 28, 2023
Risk Factors of Hyperglycemia After Treatment With the AKT Inhibitor Ipatasertib in the Prostate Cancer Setting: A Machine Learning-Based Investigation.

Rashed Harun, Rucha Sane, Kenta Yoshida

|Oct 27, 2022
Drug-Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer.

Dhruvitkumar S Sutaria, Grozdana Rasuo, Adam Harris

Pageof 2

Frequent Collaborators

3 joint publications

Rucha Sane

2 joint publications

Jürgen B Bulitta

2 joint publications

Kenta Yoshida

2 joint publications

Victor Poon